Investment company Flagship Pioneering led a $440m Series B round in Laronde, a biotech startup, with participation from T. Rowe Price Associates, Invus, Canada Pension Plan Investment Board, Fidelity Management & Research Company, BlackRock, and Federated Hermes Kaufmann Funds. "Endless RNA represents a whole new approach to making medicines and treating disease. Laronde is creating a new class of drugs that can be programmed to persistently express proteins in the body, is redosable, and can be administered through simple delivery mechanisms, resulting in highly tunable protein levels. The therapeutic possibilities enabled by eRNA are vast with the potential to greatly improve global human health. Having assembled such a knowledgeable and committed group of investors gives us the ability to not only advance this powerful technology platform but also build a transformative company to support our bold vision," Diego Miralles, Laronde Chief Executive Officer and Flagship Pioneering CEO-Partner.